



# Pharma Finance 2007

## ROMA - ITALY - MAY 10-11

# 5TH ANNUAL PARTNERING CONFERENCE

### Market Data (AS OF MAY 1, 2007)




Symbol	SUPG
Exchange	NASDAQ
Current Price	\$7.33
Shares Outstanding	55.64M
Market Capital	\$407.88M
52wk RANGE	\$3.01-\$7.04
Average Volume	632,487
YTD % Change	35%

### COMPANY FACT SHEET



**SuperGen**  
4140 Dublin Blvd. #200  
Dublin, CA 94588  
(925) 560-0100

[www.supergen.com](http://www.supergen.com)



**James S. Manuso, Ph.D.**  
Chairman, President & CEO

### FINANCIAL HIGHLIGHTS (YEAR ENDING DEC 31ST, 2006)

<b>Net Revenue:</b>	<b>38.08M</b>	<b>Earnings per Share:</b>	<b>(0.30)</b>
<b>Net Income:</b>	<b>(16.49M)</b>	<b>Weighted Average:</b>	<b>53.4M</b>

### CONFERENCE OBJECTIVES

Partnering and Licensing opportunities.

### RECENT DEVELOPMENTS

**April 4, 2007**

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR

**April 3, 2007**


Nipent(R) Acquisition by Hospira is Complete

**February 5, 2007**

SuperGen to Present at the Ninth Annual BIO CEO & Investor Conference

### PRODUCT AND PRODUCT CANDIDATE PIPELINE

#### Development Pipeline



#### MP470 - Multi-Targeted Tyrosine Kinase Inhibitor

Activating or gain-of-function mutations in the c-Kit proto-oncogene have been identified in a variety of tumors including gastrointestinal stromal tumors (GIST), a very difficult tumor type to treat. MP470 was developed to specifically bind to mutant forms of the c-Kit receptor which are insensitive to current therapies. While a potent inhibitor of wild-type c-Kit, MP470 displays even greater effectiveness against clinically relevant mutants, including V560G, D816V, N822K and K642E, due to its unique binding mode. MP470 is completing late-stage IND-enabling studies, for entry into the clinic in 2007.

### Company Description

SuperGen is a pharmaceutical company whose mission is to prolong, improve the quality of and ultimately, save the lives of those people afflicted with life-threatening diseases, especially cancer.

The company possesses a broad portfolio of proprietary cancer therapies that target a variety of solid tumors, hematological malignancies and blood disorders, offering renewed hope to patients who suffer from these illnesses...